STADA and Xbrane announced they are supplying Ximluci® (a biosimilar to Roche/Genentech’s Lucentis® (ranibizumab)) in England under a NHS England Framework Agreement. Ximluci® is indicated for the treatment of retinal vascular disorders, including wet age-related macular degeneration, diabetic macular oedema, diabetic retinopathy, retinal vein occlusion and visual impairment due to choroidal neovascularization. STADA is responsible for commercializing Ximluci® across Europe and Xbrane is responsible for commercial supply.
On 3 April 2023 Stada and Xbrane announced the continental European launch of Ximluci®.
Print Page Mail Article